**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78270

**Manuscript Type:** CASE REPORT

**Relationship of familial cytochrome P450 4V2 gene mutation with liver cirrhosis: A case report and review of the literature**

Jiang JL *et al*. Familial CYP4V2 mutation and cirrhosis

Jin-Lian Jiang, Jiang-Fu Qian, De-Hui Xiao, Xia Liu, Fang Zhu, Jie Wang, Zhou-Xiong Xing, De-Lin Xu, Yuan Xue, Yi-Huai He

**Jin-Lian Jiang, Xia Liu, Jie Wang, Yi-Huai He,** Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China

**Jiang-Fu Qian, De-Hui Xiao, Fang Zhu,** Department of Digestion, Dafang County People’s Hospital, Bijie 551600, Guizhou Province, China

**Zhou-Xiong Xing,** Department of Intensive Care, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China

**De-Lin Xu,** Department of Cell Biology, Zunyi Medical University, Zunyi 563099, Guizhou Province, China

**Yuan Xue,** Department of Liver Diseases, the Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, China

**Author contributions:** Jiang JL and Qian JF contributed equally to this work; Jiang JL, Qian JF, Xiao DH, and Zhu F collected medical history; Liu X and Wang J summarized and analyzed the medical history data; He YH and Jiang JL conceived and designed the content of the article; Jiang JL and Qian JF wrote the initial paper; He YH, Xu DL, Xue Y, and Xing ZX revised the paper; He YH had primary responsibility for final content; all authors read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 82160370; and the Science and Technology Planning Projects of Guizhou Province and Zunyi City, No. QKHJC-ZK[2022]YB642, No. ZSKH·HZ(2022)344, No. gzwjkj2020-1-041, and No. ZMC·YZ[2018]38.

**Corresponding author: Yi-Huai He, MM, Director,** Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, No. 201 Dalian Street, Zunyi 563003, Guizhou Province, China. 993565989@qq.com

**Received:** June 17, 2022

**Revised:** August 2, 2022

**Accepted: August 25, 2022**

**Published online:**

**Abstract**

BACKGROUND

Many genetic and metabolic diseases affect the liver, but diagnosis can be difficult because these diseases may have complex clinical manifestations and diverse clinical patterns. There is also incomplete clinical knowledge of these many different diseases and limitations of current testing methods.

CASE SUMMARY

We report a 53-year-old female from a rural area in China who was hospitalized for lower limb edema, abdominal distension, cirrhosis, and hypothyroidism. We excluded the common causes of liver disease (drinking alcohol, using traditional Chinese medicines, hepatitis virus infection, autoimmunity, and hepatolenticular degeneration). When she was 23-years-old, she developed night-blindness that worsened to complete blindness, with no obvious cause. Her parents were first cousins, and both were alive. Analysis of the patient’s family history indicated that all 5 siblings had night blindness and impaired vision; one sister was completely blind; and another sister had night-blindness complicated with cirrhosis and subclinical hypothyroidism. Entire exome sequencing showed that the patient, parents, and siblings all had mutations in the cytochrome P450 4V2 gene (*CYP4V2*). The *CYP4V2* mutations of the parents and two sisters were heterozygous, and the others were homozygous. Two siblings also had heterozygous dual oxidase activator 2 (*DUOXA2*) mutations.

CONCLUSION

Mutations in the *CYP4V2* gene may affect lipid metabolism and lead to chronic liver injury, fibrosis, and cirrhosis.

**Key Words:** Cirrhosis; Genetic metabolic liver disease; Cytochrome P450 4V2; Dual Oxidase activator 2; Bietti Crystalline corneoretinal dystrophy; Case report

Jiang JL, Qian JF, Xiao DH, Liu X, Zhu F, Wang J, Xing ZX, Xu DL, Xue Y, He YH. Relationship of familial cytochrome P450 4V2 gene mutation with liver cirrhosis: A case report and review of the literature. *World J Clin Cases* 2022; In press

**Core Tip:** We describe two patients from consanguineous parents who had liver cirrhosis, were completely blind, and had familial mutations in the cytochrome P450 4V2 (*CYP4V2*)gene. The four other siblings of these patients were night-blind, and one also had cirrhosis. *CYP4V2* functions in hepatic lipid metabolism and inflammatory responses. We suggest that this *CYP4V2* gene mutation affects hepatic lipid metabolism and inflammatory responses, which leads to chronic liver injury and may subsequently progress to liver fibrosis and cirrhosis.

**INTRODUCTION**

“Liver disease of unknown cause” includes a wide range of pathologies. The specific history of a patient, laboratory results, and liver biopsy results can help to identify common liver diseases, such as autoimmune liver disease, drug-induced liver damage, and non-alcoholic fatty liver disease. Genetic metabolic liver disease (GLD) accounts for about 1% of all cases of unexplained liver disease. GLD is characterized by metabolic abnormalities and incomplete liver function[1] , which may occur due to consanguinity, and is characterized by early liver involvement, extensive liver damage, and is often accompanied by damage of other organs. Diagnosis of GLD is most common in children, but symptoms may manifest at any age.

GLD usually results from the combined effects of genetic and environmental factors. The liver typically has a good compensatory function, and some of these patients may be asymptomatic under normal physiological conditions, with no evidence of abnormal liver function or late onset of liver disease. Thus, the possibility of a GLD in an adult who presents with an unknown liver disease or cirrhosis should be considered[[2](#_ENREF_2),[3](#_ENREF_3)]. Most GLDs are autosomal recessive diseases, although some are autosomal dominant, X-linked, or mitochondrial diseases[[4](#_ENREF_4)]. The absence of a family history of liver disease cannot exclude the possibility of GLD.

Diagnosis of GLDs is difficult in clinical practice due to their rarity, complex and wide spectrum of clinical manifestations, significant individual differences, and insufficient clinical understanding and limitations of testing methods[[5](#_ENREF_5),[6](#_ENREF_6)]. At present, there are more than 600 kinds of GLD, including primary hemochromatosis, hepatolenticular degeneration, hereditary hemochromatosis, glycogen storage disease, α1-antitrypsin deficiency, hereditary hyperbilirubinemia, Dubin-Johnson syndrome, Rotor syndrome, hereditary hyperbilirubinemias, and congenital liver fibrosis[[7](#_ENREF_7)]. At onset, GLD most commonly manifests as a chronic disease, but acute disease may occur under certain circumstances. Some laboratory and imaging tests can identify genetic abnormalities and can be used to diagnose certain hereditary metabolic diseases[[8](#_ENREF_8)]. In particular, some GLD can be confirmed by measurements of specific enzymes in the serum, skin fibroblasts, or liver tissue cells[[9](#_ENREF_9)]. Pathological examination and gene testing are also very important for the diagnosis of GLD.

**CASE PRESENTATION**

***Chief complaints***

The patient was admitted for recurrent lower extremity edema for 9 mo, abdominal distension for 7 mo, and aggravation for half a month.

***History of present illness***

A 53-year-old rural Chinese woman visited Dafang County People’s Hospital. Symptoms began to appear nine months ago, during which edema and abdominal distension of both lower extremities recurred, and these gradually worsened during the previous two months. Our initial liver function examination showed elevated alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL); decreased albumin/globulin (ALB/GLO) ratio (Table 1). Examination of blood cells indicated decreased white blood cells (WBCs), red blood cells (RBCs), hemoglobin (HB), and platelets (PLTs) (Table 2). Examination of coagulation function indicated an increased international normalized ratio (INR), prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), and decreased fibrinogen (FIB) (Table 3). An upper abdominal computed tomography (CT) showed liver cirrhosis (Figure 1). Examination of thyroid function showed an elevated level of thyroid stimulating hormone (TSH) and a decreased level of free triiodothyronine (FT3) (Table 4). We therefore initially considered a diagnosis of “decompensated stage of cirrhosis and subclinical hypothyroidism”.

She tested negative for hepatitis viruses and negative for autoimmune hepatitis, and the cause of cirrhosis was unknown. She was subsequently hospitalized twice for abdominal distension with yellow staining of the sclera, but these symptoms resolved after administration of a liver protectant and a diuretic to reduce swelling. After discharge, she still reported repeated abdominal distension and discomfort, which gradually became worse from 2020 Oct 1. Since the initial presentation, her liver function indexes have fluctuated. The thyroid function tests indicated a decreasing level of triiodothyronine (T3) and an increasing level of TSH, indicating progression from subclinical hypothyroidism to clinical hypothyroidism.

***History of past illness***

She reported loss of vision 30 years ago, with no obvious cause, and had no history of long-term heavy drinking, taking a Chinese medicine, exposure to toxic substances, surgery, or trauma.

***Personal and family history***

We designated the index patient as proband II-1, and analyzed her pedigree (Figure 2). She had five siblings (3 sisters, 2 brothers), all of whom had night blindness, and one sister (II-4) was completely blind. Her parents had no night blindness or impaired vision, but their marriage was consanguineous (first cousins).

We performed serum biochemical examinations of the father (I-1) and all siblings (Table 5). The mother (I-2) was too old to travel to our institution for testing. The AST level was elevated in all 7 individuals, and fasting blood glucose was decreased in the father and 4 siblings. Two siblings had elevated levels of high density lipoprotein cholesterol (HDL-C), and one had a low level. The T3 Level was low in two siblings, and the TSH level was high in three siblings. Some of the siblings also had elevated levels of TBIL and apolipoprotein A-I (APOA1).

CT examinations showed that neither the father (I-1) nor the mother (I-2) had cirrhosis (Figure 3A and B). Sibling II-2 had cirrhosis (Figure 3C), but siblings II-3, II-5, and II-6 did not (Figure 3D-F). Abdominal color ultrasound indicated that sibling II-4 had a fatty liver.

***Physical examination***

A physical examination indicated she had a BMI of 22.22. There was also evidence of chronic liver disease, visible spider nevi, and palmar erythema. She had no vision in either eye, and no K-F rings in the corneas. A cardiopulmonary examination showed no obvious abnormalities. Her abdomen was slightly distensible and was positive for shifting dullness. There was moderate pitting edema in both lower limbs.

***Laboratory examinations***

2020 Oct 14: Blood lipid analysis indicated an HDL of 1.42 mmol/L. Hepatitis A virus, hepatitis B virus, and hepatitis C virus related tests were all negative.

2021 Jan 17: All antibody tests for autoimmune liver diseases were negative.

2021 Jul 16: Examination of ascites indicated the Rivalta test was negative, the WBC count was 50 × 106/L, total protein (TP) was 5.50 g/L, adenosine deaminase (ADA) was 3.4 U/L, glucose (GLU) was 8.71 mmol/L, and lactate dehydrogenase (LDH) was 48.8 U/L.

***Imaging examinations***

2020 Oct 15: Color Doppler ultrasonography of the thyroid showed bilateral thyroid cysts.

2020 Oct 23: A plain CT scan of the upper abdomen with enhancement showed cirrhotic ascites with splenomegaly (Figure 1).

We suggested more extensive examination of a liver biopsy to clarify the cause of cirrhosis, but this was not possible because the patient did not consent. The index patient was one of 6 siblings; II-2 was similar (night blindness complicated with cirrhosis and hypothyroidism), II-5 was completely blind in both eyes, and the other three had obvious night blindness. We considered the possibility of GLD, and suggested molecular genetic analysis. After receiving informed consent, we collected peripheral blood samples for whole-exome sequencing (Figure 4, Table 6). The results indicated the presence of the deletion/insertion mutation C.802-8\_810delinsGC (homozygous) in the cytochrome P450 4V2 (*CYP4V2*) gene and the transcoding mutation C.413dupA (heterozygous) in the dual oxidase activator 2 (*DUOXA2*) gene. The same *CYP4V2* mutation was present in I-1, I-2, II-2, II-3, II-5, II-6, II-3, and II-5 also had the *DUOXA2* mutation. Patient II-4 did not receive genetic testing because he lived in Tianjin.

**FINAL DIAGNOSIS**

Combined with the patient’s medical history, the final diagnosis was decompensated active cirrhosis and hypothyroidism.

**TREATMENT**

Drugs were given to protect the liver, reduce jaundice, and promote diuresis to eliminate ascites.

**OUTCOME AND FOLLOW-UP**

After discharge, the patient continued to experience abdominal distension and jaundice repeatedly, and the treatments had limited efficacy.

**DISCUSSION**

We used whole exome sequencing to identify a *CYP4V2* gene mutation in the index patient and in her parents and siblings. Both parents were heterozygous for the mutation, and had no night blindness or vision loss. Among the five siblings of the index patient (II-1), II-2 and II-5 were heterozygous, II-3 and II-6 were homozygous, and all of them had night blindness or more severe visual impairment. Patients II-1, II-3, and II-5 also had a *DUOXA2* heterozygous mutation, but II-2 and II-6 only had the *CYP4V2* mutations. Notably, upper abdominal CT of II-1 and II-2 indicated liver cirrhosis. *CYP4V2* is in the cytochrome P450 family, and functions in the hydroxylation of long-chain fatty acids and in anti-inflammatory reactions. This suggests that a defective *CYP4V2* gene may cause chronic liver injury by altering fatty acid metabolism and increasing inflammation in the liver, which subsequently progresses to liver fibrosis and cirrhosis.

The *CYP4V2* gene has 11 exons, is located at 4q35.1-q35.2, encodes a protein with 525 amino acids, and is expressed in almost all tissues and organs of the human body. It has high expression in the retinal pigment epithelium (RPE) and in cultured RPE cells (ARPE-19), but is only rarely detected in the corneal epithelium. The outer section of the retina contains a disc membrane rich in rhodopsin, and the lipids of these discs are mostly palmitic acid, stearic acid, oleic acid, and docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA) is a minor retinal lipid. CYP4V2 dominates the metabolism of EPA and DHA in the retina[[10](#_ENREF_10)].

A pathogenic variation of *CYP4V2* can lead to Bietti crystalline corneal and retinal dystrophy (BCD), a disease with autosomal recessive inheritance. BCD is characterized by choroidal retinal degeneration with yellow-white crystals or complex lipid deposits in the retina and cornea. BCD is rare in Caucasians, but has a higher prevalence in Asians. It is a progressive disease, and most patients experience some vision loss at the age of 10 to 40 years-old, and legal blindness often occurs when the patient is 40 or 50 years-old[[11](#_ENREF_11)]. The *CYP4V2* gene functions in the decomposition and elimination of fatty acids from the retina, so a mutation in this gene presumably affects lipid metabolism in the RPE. At the age of 23, the index patient had gradually decreased vision, and she developed legal blindness when she was 30 years-old. The other five siblings all had different degrees of visual impairment (mainly night blindness), although one of them was completely blind. These findings are consistent with the clinical characteristics of BCD.

*CYP4V2* hashigh expression in the RPE and in tissues and cells that function in the metabolism of fatty acids and steroids, such as hepatocytes, the thyroid, and islet cells[[12](#_ENREF_12)]. However, the *CYP4V2* mutation responsible for BCD has little effect on these other tissues and organs[[13](#_ENREF_13)]. There is evidence that BCD patients have increased serum levels of triglycerides (TGs), total cholesterol (TC), and low density lipoprotein cholesterol (LDL-C)[[14](#_ENREF_14)]. Previous research reported that *CYP4V2* was a selective hydroxylase of saturated medium-chain fatty acids, and had high catalytic efficiency for creatine and lauric acid[[15](#_ENREF_15)]. In addition, *CYP4V2* expression is also associated with production of arachidonic acid ω-hydroxylase, suggesting it may contribute to arachidonic acid metabolism. There is also evidence that overexpression of functional *CYP4V2* alters lipid homeostasis in cultured liver cancer cells (Hep G2). In particular, the levels of EPA and DHA were significantly increased in Hep G2 cells that expressed the mutant enzyme *CYP4V2*[[10](#_ENREF_10)]. These many studies indicate that *CYP4V2* functions in fat metabolism, is strongly expressed in the liver, and that mutations can affect liver fatty acid metabolism. In agreement, we found abnormalities in the blood lipids of the index patient and her family, and the level of HDL-C was high or borderline-high in patients II-1, II-2, II-5, and II-6, although the molecular mechanism of this effect remains unclear. However, elevated HDL-C promotes reverse transport of peripheral cholesterol into the liver, and thus increases hepatic cholesterol accumulation. Long-term disorders of fatty acid metabolism that lead to hepatic lipid accumulation can cause or exacerbate liver disease.

There is evidence that leukotriene B4 (LTB4) reduces the uptake of free fatty acids by adipocytes, and increases leukocyte tissue infiltration and inflammatory responses *via* the production of inflammatory cytokines and chemokines, thus contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)[[16](#_ENREF_16)]. CYP ω-hydroxylase converts LTB4 into its 20-hydroxyl metabolite (20-OH LTB4), which reduces chemotactic activity against leukocytes. Notably, research indicated the activity of CYP ω-hydroxylase was significantly decreased and the level of LTB4 was significantly increased in the colonic mucosa of patients with inflammatory bowel disease[[17](#_ENREF_17),[18](#_ENREF_18)]. Other studies showed that reduced activity of CYP ω-hydroxylase was associated with sclerosis and atopic dermatitis[[19-21](#_ENREF_19)] and with neuroinflammation[[22](#_ENREF_22)]. All of these results are consistent with our interpretation that the *CYP4V2* gene mutation identified here promotes liver inflammation and injury.

The *DUOX2* gene is located at 15q15.3, contains 34 exons, encodes a protein with 1548 amino acids, and is mainly expressed in thyroid tissues. This gene functions in the iodination of thyroid hormone, and catalyzes the production of H2O2. A pathogenic variant of this gene leads to thyroid dyshormonogenesis 5 (TDH5), an autosomal recessive disorder. The clinical manifestations of this disease include partial or complete loss of thyroid function, and elevated serum levels of TSH. There is also ultrasonography evidence of goiter in these patients[[23](#_ENREF_23)]. However, mutation of the *DUOX2* gene prevents the iodination of thyroid hormone, reduces the synthesis of thyroxine, and thus leads to hypothyroidism[[24](#_ENREF_24)]. We found elevations of TSH in patients II-1, II-2, and II-4, and decreased levels of T3 in patients II-1 and II-5, consistent with mutations of the *DUOXA2* gene.

Thyroid hormone contributes to the regulation of liver triglycerides. Thyroid hormone binds to a specific thyroid hormone receptor (THR), which is a transcription factor that regulates the expression of many genes that function in adipogenesis, such as adiposynthase, ACC1, and THRSP[[25](#_ENREF_25)]. In addition, thyroxine indirectly regulates the transcription of other transcription factors, such as steroid regulatory element binding protein 1C (SREBP1C), liver X receptor (LXR), and carbohydrate reaction element binding protein (ChREBP), and thus regulates hepatic adipogenesis[[26](#_ENREF_26)]. Although thyroid hormones stimulate fat production, patients with hyperthyroidism experience a net decrease in total liver triglycerides because the rate of fatty acid metabolism exceeds that of fat synthesis.

The mobilization, degradation, and β-oxidation of fatty acids by thyroid hormones contribute to an increased overall rate of fatty acid metabolism. The release of FFA in hepatocytes is caused by cellular lysozyme activity[[27](#_ENREF_27)]. Thyroxine promotes the oxidative catabolism of hepatic fat by increasing the expression and activity of hepatic lipase and other mitochondrial enzymes required for fatty acid beta oxidation, including medium-chain acetyl-CoA dehydrogenase. In hypothyroidism, fat synthesis is reduced, but fatty acid mobilization, degradation, and oxidation are reduced even more, and this leads to the accumulation of triglycerides in the liver.

Thyroid hormone functions in the regulation of cholesterol metabolism in the liver. On the one hand, thyroid hormone can strongly induce the expression of APOA1, scavanger receptor class B member 1 (SR-B1), and steroid regulatory element binding protein 2 (SR-EBP2), thus increasing the level of low density lipoprotein receptor (LDLR). This increases the transport of cholesterol from surrounding tissues into the liver[[28](#_ENREF_28)]. On the other hand, thyroid hormone can also up-regulate hydroxymethyl glutarate monoacyl coenzyme A reductase (HMGR), thereby promoting cholesterol synthesis. The key enzyme in the transformation of cholesterol to bile acid is cholesterol 7α hydroxylase (CYP7A); thyroid hormone can increase the transcription of CYP7A, thus promoting the transformation of cholesterol to bile acid. Patients with hypothyroidism have reduced cholesterol synthesis, excretion, and transformation, but thyroid hormone has a greater effect on the LDL-C receptor than on HMGR. Thus, the overall effect of hypothyroidism is an increase in total cholesterol. In addition, patients with hypothyroidism have reduced oxidative stress and basal metabolic rate, leading to fat accumulation[[29](#_ENREF_29)].

Thyroid hormone deficiency leads to increased TSH secretion, and TSH regulation of hepatic triglyceride metabolism is independent of thyroid hormone. TSH binds to the TSHR on liver cells, activates the cAMP/PKA pathway, thus increasing the expression and activity of SREBP-1C and triglyceride synthesis and promoting hepatocyte steatosis[[30](#_ENREF_30)]. TSH also inhibits the synthesis of liver bile acids *via* the SREBP2/HNF4/CYP7A1 signaling pathway, resulting in reduced cholesterol conversion. As an upstream molecule, TSH increases hepatic gluconeogenesis and HMGC receptor (HMGCR) expression by regulating the cAMP/PKA/CREB signaling pathway, and it also promotes cholesterol and triglyceride synthesis[[31-33](#_ENREF_31)]. Hypothyroidism can lead to chronic liver disorders in glycolipid metabolism, and the subsequent accumulation of triglycerides and cholesterol in the liver can lead liver disease. Promotes synthesis of triglycerides and cholesterol.

Our results indicated that a *CYP4V2* gene mutation disrupted lipid metabolism in the liver, presumably due to an increase in inflammation. A *DUOXA2* gene mutation causes insufficient thyroxine production and secondary TSH secretion, and these also affect glucose and lipid metabolism. Thus, mutations of both genes lead to even greater dysregulation of sugar and fat metabolism and contribute to chronic liver inflammation and injury. Two siblings in the family (II-1 and II-2) had cirrhosis. However, patient II-1 had mutations in both genes, but II-2 only had the *CYP4V2* mutation. This suggests that the *CYP4V2* mutation may have a stronger effect in causing chronic liver injury.

The onset of GLD usually occurs at an early age, but two patients in the family were more than 50 years-old. The mutations of the *CYP4V2* or *DUOXA2* genes described here may not have directly caused liver damage, but instead may have directly or indirectly altered the metabolism of glucose and lipids in the liver, thereby increasing liver inflammation. Notably, the index patient lived in a rural area with poor living conditions and had a low-fat diet, conditions that may be conducive to slowing the progression of liver disease. This may be one of the reasons for her late onset of liver disease. The mutations of the *CYP4V2* or *DUOXA2* genes indicated they have important functions in liver fat metabolism, and suggest there should also be hepatocyte steatosis. However, our color ultrasound and upper abdominal CT examinations did not indicate a fatty liver. We wanted to conduct a liver biopsy for confirmation, but the patient refused. The lack of a complete pathological diagnosis is thus a deficiency of our study. The apparent lack of a fatty liver in the index patient might be because the patient was close to end-stage cirrhosis, had a poor diet after disease onset, delayed seeking medical care, and did not show metabolic abnormalities. Although we examined the presence of GLD and *CYP4V2* gene mutations in 8 individuals from a consanguineous family, it is generally considered necessary to analyze 3 separate families to establish a causal relationship. Unfortunately, this is often impossible for very rare conditions.

**CONCLUSION**

GLD is rare and can have complex clinical manifestations. This case report provides an improved understanding of one type of GLD. The onset of symptoms in patients with GLD can occur at any age, so the possibility of GLD should also be considered in adult patients who present with unexplained liver disease or cirrhosis. The diagnosis of GLD requires careful examination of clinical manifestations, a comprehensive analysis of family history, assessment of symptoms and signs in family members, and detailed pathological examinations and genetic testing. Clinicians who encounter patients with “liver disease of unknown cause” should therefore consider GLD, regardless of patient age.

**REFERENCES**

1 **Kim JS**, Kim KM, Oh SH, Kim HJ, Cho JM, Yoo HW, Namgoong JM, Kim DY, Kim KH, Hwang S, Lee SG. Liver transplantation for metabolic liver disease: experience at a living donor dominant liver transplantation center. *Pediatr Gastroenterol Hepatol Nutr* 2015; **18**: 48-54 [PMID: 25866733 DOI: 10.5223/pghn.2015.18.1.48]

2 **Song P**, Gao J, Inagaki Y, Kokudo N, Tang W. Intractable and rare diseases research in Asia. *Biosci Trends* 2012; **6**: 48-51 [PMID: 22621985]

3 **Wong LJ**, Scaglia F, Graham BH, Craigen WJ. Current molecular diagnostic algorithm for mitochondrial disorders. *Mol Genet Metab* 2010; **100**: 111-117 [PMID: 20359921 DOI: 10.1016/j.ymgme.2010.02.024]

4 **Cox C**, Bosley M, Southerland LB, Ahmadi S, Perkins J, Roman S, Sosa JA, Carneiro-Pla D. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? *Surgery* 2018; **163**: 75-80 [PMID: 29122328 DOI: 10.1016/j.surg.2017.04.039]

5 **Alam S**, Sood V. Metabolic Liver Disease: When to Suspect and How to Diagnose? *Indian J Pediatr* 2016; **83**: 1321-1333 [PMID: 27130505 DOI: 10.1007/s12098-016-2097-z]

6 **Yamaguchi K**, Wakimizu R, Kubota M. Difficulties in Daily Life and Associated Factors, and QoL of Children with Inherited Metabolic Disease and Their Parents in Japan: A Literature Review. *JIMD Rep* 2017; **33**: 1-10 [PMID: 27344649 DOI: 10.1007/8904\_2016\_573]

7 **Roberts EA**, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. *Hepatology* 2008; **47**: 2089-2111 [PMID: 18506894 DOI: 10.1002/hep.22261]

8 **Xiong QF**, Yang YF. [Histopathological features and diagnostic considerations for genetic metabolic liver disease]. *Zhonghua Gan Zang Bing Za Zhi* 2018; **26**: 885-888 [PMID: 30669778 DOI: 10.3760/cma.j.issn.1007-3418.2018.12.002]

9 **Koenig MK**. Presentation and diagnosis of mitochondrial disorders in children. *Pediatr Neurol* 2008; **38**: 305-313 [PMID: 18410845 DOI: 10.1016/j.pediatrneurol.2007.12.001]

10 **Nakano M**, Kelly EJ, Wiek C, Hanenberg H, Rettie AE. CYP4V2 in Bietti’s crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. *Mol Pharmacol* 2012; **82**: 679-686 [PMID: 22772592 DOI: 10.1124/mol.112.080085]

11 **Wang W**, Chen W, Bai X, Chen L. Multimodal imaging features and genetic findings in Bietti crystalline dystrophy. *BMC Ophthalmol* 2020; **20**: 331 [PMID: 32799831 DOI: 10.1186/s12886-020-01545-3]

12 **Jarrar YB**, Lee SJ. Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications. *Int J Mol Sci* 2019; **20** [PMID: 31480463 DOI: 10.3390/ijms20174274]

13 **García-García GP**, Martínez-Rubio M, Moya-Moya MA, Pérez-Santonja JJ, Escribano J. Current perspectives in Bietti crystalline dystrophy. *Clin Ophthalmol* 2019; **13**: 1379-1399 [PMID: 31440027 DOI: 10.2147/OPTH.S185744]

14 **Nakano M**, Lockhart CM, Kelly EJ, Rettie AE. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. *Drug Metab Rev* 2014; **46**: 247-260 [PMID: 24856391 DOI: 10.3109/03602532.2014.921190]

15 **Nakano M**, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. *Drug Metab Dispos* 2009; **37**: 2119-2122 [PMID: 19661213 DOI: 10.1124/dmd.109.028530]

16 **Horrillo R**, González-Périz A, Martínez-Clemente M, López-Parra M, Ferré N, Titos E, Morán-Salvador E, Deulofeu R, Arroyo V, Clària J. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. *J Immunol* 2010; **184**: 3978-3987 [PMID: 20207999 DOI: 10.4049/jimmunol.0901355]

17 **Costea I**, Mack DR, Israel D, Morgan K, Krupoves A, Seidman E, Deslandres C, Lambrette P, Grimard G, Levy E, Amre DK. Genes involved in the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn’s disease in children &amp; young adults. *PLoS One* 2010; **5**: e15672 [PMID: 21187935 DOI: 10.1371/journal.pone.0015672]

18 **Curley CR**, Monsuur AJ, Wapenaar MC, Rioux JD, Wijmenga C. A functional candidate screen for coeliac disease genes. *Eur J Hum Genet* 2006; **14**: 1215-1222 [PMID: 16835590 DOI: 10.1038/sj.ejhg.5201687]

19 **Du L**, Yin H, Morrow JD, Strobel HW, Keeney DS. 20-Hydroxylation is the CYP-dependent and retinoid-inducible leukotriene B4 inactivation pathway in human and mouse skin cells. *Arch Biochem Biophys* 2009; **484**: 80-86 [PMID: 19467632 DOI: 10.1016/j.abb.2009.01.012]

20 **Kalsotra A**, Du L, Wang Y, Ladd PA, Kikuta Y, Duvic M, Boyd AS, Keeney DS, Strobel HW. Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways. *FASEB J* 2008; **22**: 538-547 [PMID: 17884973 DOI: 10.1096/fj.07-9244com]

21 **Zhang X**, Hardwick JP. Regulation of CYP4F2 leukotriene B4 omega-hydroxylase by retinoic acids in HepG2 cells. *Biochem Biophys Res Commun* 2000; **279**: 864-871 [PMID: 11162441 DOI: 10.1006/bbrc.2000.4020]

22 **Sehgal N**, Agarwal V, Valli RK, Joshi SD, Antonovic L, Strobel HW, Ravindranath V. Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation. *Biochem Pharmacol* 2011; **82**: 53-64 [PMID: 21466787 DOI: 10.1016/j.bcp.2011.03.025]

23 **Zamproni I**, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, Onigata K, Fugazzola L, Refetoff S, Persani L, Weber G. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. *J Clin Endocrinol Metab* 2008; **93**: 605-610 [PMID: 18042646 DOI: 10.1210/jc.2007-2020]

24 **Vaisman M**, Rosenthal D, Carvalho DP. [Enzymes involved in thyroid iodide organification]. *Arq Bras Endocrinol Metabol* 2004; **48**: 9-15 [PMID: 15611814 DOI: 10.1590/s0004-27302004000100003]

25 **Radenne A**, Akpa M, Martel C, Sawadogo S, Mauvoisin D, Mounier C. Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 genomic and nongenomic actions. *Am J Physiol Endocrinol Metab* 2008; **295**: E884-E894 [PMID: 18682535 DOI: 10.1152/ajpendo.90438.2008]

26 **Wang Y**, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. *Nat Rev Mol Cell Biol* 2015; **16**: 678-689 [PMID: 26490400 DOI: 10.1038/nrm4074]

27 **Quiroga AD**, Lehner R. Liver triacylglycerol lipases. *Biochim Biophys Acta* 2012; **1821**: 762-769 [PMID: 21963564 DOI: 10.1016/j.bbalip.2011.09.007]

28 **Lopez D**, Abisambra Socarrás JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. *Biochim Biophys Acta* 2007; **1771**: 1216-1225 [PMID: 17572141 DOI: 10.1016/j.bbalip.2007.05.001]

29 **Messarah M**, Boumendjel A, Chouabia A, Klibet F, Abdennour C, Boulakoud MS, Feki AE. Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats. *Exp Toxicol Pathol* 2010; **62**: 301-310 [PMID: 19540741 DOI: 10.1016/j.etp.2009.04.009]

30 **Yan F**, Wang Q, Lu M, Chen W, Song Y, Jing F, Guan Y, Wang L, Lin Y, Bo T, Zhang J, Wang T, Xin W, Yu C, Guan Q, Zhou X, Gao L, Xu C, Zhao J. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. *J Hepatol* 2014; **61**: 1358-1364 [PMID: 25016220 DOI: 10.1016/j.jhep.2014.06.037]

31 **Li Y**, Wang L, Zhou L, Song Y, Ma S, Yu C, Zhao J, Xu C, Gao L. Thyroid stimulating hormone increases hepatic gluconeogenesis *via* CRTC2. *Mol Cell Endocrinol* 2017; **446**: 70-80 [PMID: 28212844 DOI: 10.1016/j.mce.2017.02.015]

32 **Zhang X**, Song Y, Feng M, Zhou X, Lu Y, Gao L, Yu C, Jiang X, Zhao J. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation *via* AMP-activated protein kinase in the liver. *J Lipid Res* 2015; **56**: 963-971 [PMID: 25713102 DOI: 10.1194/jlr.M047654]

33 **Duntas LH**, Brenta G. A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism. *Front Endocrinol (Lausanne)* 2018; **9**: 511 [PMID: 30233497 DOI: 10.3389/fendo.2018.00511]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patients for the publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 17, 2022

**First decision:** July 12, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C, C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Kreisel W, Germany; Kumar R, India; Maslennikov R, Russia **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL


**Figure Legends**




**Figure 1 Computed tomography images of the upper abdomen of the index patient (II-1).** A: Enhanced computed tomography (CT) (2020 Oct 23): The proportions of liver were disordered, the contour was not regular, and there was no obvious enhancement of liver parenchyma; the spleen was enlarged; a fluid density shadow was evident in the abdominal cavity; B: Scanning CT (2021 Oct 11): A fluid density shadow was present at the edge of liver; liver volume was increased; a liver fissure was widened, with uneven and blunt edges and no abnormal density foci; the spleen was enlarged and parenchyma density was uniform.



**Figure 2 Pedigree of the index patient (II-1).** Square: Male; Circle: Female; White symbol: Normal vision; Gray symbol: Night blindness; Black symbol: Completely blind; Bordered symbol: Cirrhosis; Arrow: Proband; Two horizontal lines: Inbreeding of first cousins.



**Figure 3 Computed tomography images of the upper abdomens of six family members.** A and B: I-1, I-2 (2022 Jan 20): The size and shape of liver and spleen were normal, and there was no obvious enhancement on enhanced scan; C: II-2 (2021 Oct 11): The proportions of the liver lobes were disordered and the contour was not regular; multiple low-density shadows were on the boundary, and elliptic shapes with different sizes were observed in liver, with a computed tomography (CT) value of about 13 HU; the spleen volume was significantly increased and the parenchyma density was uniform; there was no fluid accumulation in the abdominal cavity; D-F: II-3, II-4, and II-5 (2021 Oct 11): The liver was normal in size and shape had a smooth surface and a uniform density of parenchyma; the spleen was normal in size and density.



**Figure 4 Sanger sequencing results of cytochrome P450 4V2** **in patients II-1, I-1, and I-2.** The *CYP4V2* in patient II-1 is a deletion/insertion mutation of C.802-8\_810delinsGC that leads to the early termination of translation.

**Table 1 Changes of liver function indicators in the index patient**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Date** | **ALT, U/L** | **AST, U/L** | **TBIL, μmol/L** | **DBIL, μmol/L** | **IBIL μmol/L** | **GGT, U/L** | **ALP, U/L** | **ALB, g/L** | **GLO, g/L** |
| **Ref: 0-40** | **Ref: 0-34** | **Ref: 5.1-19.0** | **Ref: 1.7-6.8** | **Ref: 1.7-13.2** | **Ref: 0-50** | **Ref: 40-150** | **Ref: 38-51** | **Ref: 20-30** |
| 2020-10-14 | 89.9↑ | 259.6↑ | 94.13↑ | 44.45↑ | 49.68↑ | 40.70 | 178.7↑ | 25.30↓ | 51.7↑ |
| 2020-10-20 | 58.9↑ | 164.7↑ | 90.92↑ | 39.89↑ | 51.03↑ | 35.77 | 158.5↑ | 33.03↓ | 43.0↑ |
| 2021-01-14 | 86.9↑ | 182.5↑ | 109.91↑ | 60.62↑ | 49.28↑ | 37.60 | 69.9 | 21.20↓ | 55.3↑ |
| 2021-01-26 | 61.0↑ | 159.2↑ | 71.90↑ | 44.26↑ | 27.64↑ | 28.60 | 87.5 | 27.70↓ | 30.0 |
| 2021-04-18 | 63.7↑ | 204.4↑ | 102.32↑ | 68.26↑ | 34.06↑ | 31.40 | 117.4 | 24.00↓ | 35.6↑ |
| 2021-04-25 | 46.2↑ | 151.8↑ | 79.40↑ | 53.25↑ | 26.15↑ | 28.80 | 105.3 | 30.60↓ | 32.3↑ |
| 2021-07-14 | 53.3↑ | 164.7↑ | 95.24↑ | 65.73↑ | 29.51↑ | 34.00 | 116.7 | 25.30↓ | 34.7↑ |
| 2021-07-25 | 36.72 | 113.5↑ | 80.00↑ | 57.63↑ | 22.37↑ | - | - | 33.78↓ | 27.7 |

Here and below: Bold number with upward arrow, abnormally high; bold number with downward arrow, abnormally low. ALT: Alanine transaminase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; GGT: Gamma glutamyl transpeptidase; ALP: Alkaline phosphatase; ALB: Albumin; GLO: Globulin.

**Table 2 Changes of blood cell counts and hemoglobin in the index patient**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Date** | **WBCs, × 109/L** | **RBCs, × 1012/L** | **HB, g/L** | **PLTs, × 109/L** |
| **Ref: 3.5-9.5** | **Ref: 3.8-5.1** | **Ref: 115-150** | **Ref: 125-350** |
| 2020-10-14 | 3.25↓ | 3.5↓ | 120 | 62↓ |
| 2021-01-13 | 8.94 | 3.3↓ | 122 | 46↓ |
| 2021-01-26 | 2.56↓ | 2.8↓ | 97↓ | 50↓ |
| 2021-04-18 | 3.21↓ | 2.9↓ | 102↓ | 58↓ |
| 2021-04-22 | 2.49↓ | 2.7↓ | 108↓ | 51↓ |
| 2021-07-14 | 3.13↓ | 3.0↓ | 105↓ | 56↓ |

HB: Hemoglobin; PLTs: Platelets; RBCs: Red blood cells; WBCs: White blood cells.

**Table 3 Changes of coagulation function indicators in the index patient**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Date** | **INR** | **PT, s** | **APTT, s** | **FIB, g/L** |
| **Ref: 0.8-1.3** | **Ref: 10.0-15.0** | **Ref: 21.0-35.0** | **Ref: 2.0-4.0** |
| 2020-10-14 | 1.53↑ | 17.03↑ | 56.73↑ | 1.54↓ |
| 2021-01-13 | 1.25 | 15.60↑ | 31.63 | 2.06 |
| 2021-01-26 | 1.47↑ | 17.90↑ | 38.77↑ | 1.24↓ |
| 2021-04-18 | 1.54↑ | 18.79↑ | 42.95↑ | 1.30↓ |
| 2021-04-22 | 1.58↑ | 19.36↑ | 43.93↑ | 1.18↓ |
| 2021-07-15 | 1.43↑ | 17.02↑ | 39.93↑ | 1.37↓ |

APTT: Activated partial thromboplastin time; FIB: Fibrinogen; INR: International normalized ratio; PT: Prothrombin time.

**Table 4 Changes of thyroid function indicators in the index patient**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Date** | **T3, ng/mL** | **T4, µg/dL** | **FT3, pg/mL** | **FT4, ng/dL** | **TSH, µIU/mL** |
| **Ref: 1.3-3.1** | **Ref: 5.0-14.5** | **Ref: 2.3-4.0** | **Ref: 0.6-1.2** | **Ref: 0.35-5.10** |
| 2020-10-14 | 0.66↓ | 9.27 | 2.14↓ | 0.94 | 5.18↑ |
| 2021-01-13 | 0.62↓ | 7.65 | 2.17↓ | 0.96 | 4.74 |
| 2021-07-26 | 0.43↓ | 5.62 | 1.57↓ | 0.91 | 6.56↑ |

FT3: Free triiodothyronine; FT4: Free thyroxine; T3: Triiodothyronine; T4: Thyroxine; TSH: Thyroid stimulating hormone.

**Table 5 Serological test results of the index patient (II-1) and her relatives**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **ALT, U/L** | **AST, U/L** | **TBIL, μmol/L** | **HDL-C, mmol/L** | **APOA1, g/L** | **T3, ng/mL** | **TSH, µIU/mL** |
| **Ref:0-40** | **Ref: 0-34** | **Ref: 5.1-19.0** | **Ref: 1.29-1.55** | **Ref: 1.0-1.6** | **Ref: 1.3-3.1** | **Ref: 0.35-5.1** |
| I-1 | 23 | 41↑ | 10.1 | 1.51 | 1.57 | 1.74 | 2.99 |
| II-1 | 53.3↑ | 164.7↑ | 95.2↑ | 1.42 | 1.50 | 0.43↓ | 6.56↑ |
| II-2 | 19 | 54↑ | 18.2 | 1.88↑ | 1.79↑ | 1.96 | 6.54↑ |
| II-3 | 26 | 59↑ | 13.2 | 1.42 | 1.52 | 1.83 | 1.70 |
| II-4 | 20 | 50↑ | 29.8↑ | 1.17↓ | ND | 1.50 | 5.29↑ |
| II-5 | 10 | 28 | 22.8↑ | 1.94↑ | 1.83↑ | 1.29↓ | 1.55 |
| II-6 | 22 | 41↑ | 16.4 | 1.52 | 1.71↑ | 2.14 | 3.13 |

ALT: Alanine transaminase; APOA1: Apolipoprotein A-I; AST: Aspartate aminotransferase; HDL-C: High density lipoprotein cholesterol; T3: Triiodothyronine; TBIL: Total Bilirubin; TSH: Thyroid stimulating hormone.

**Table 6 Total exome sequencing results of gene mutations in the index patient (II-1) and her relatives**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patient** | **Gene** | **Chromosome location** | **Basic variation** | **Zygosity** | **Inheritance pattern** |
| I-1 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HTZ | AR |
| I-2 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HTZ | AR |
| II-1 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HMZ | AR |
| *DUOXA2* | chr15: 45408785 | c.413dupA | HTZ | AR |
| II-2 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HTZ | AR |
| II-3 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HMZ | AR |
| *DUOXA2* | chr15: 45408785 | c.413dupA | HTZ | AR |
| II-5 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HTZ | AR |
| *DUOXA2* | chr15: 45408785 | c.413dupA | HTZ | AR |
| II-6 | *CYP4V2* | chr4: 187122319 | c.802-8\_810delinsGC | HMZ | AR |

AR: Autosomal recessive; CYP4V2: Cytochrome P450 4V2; DUOXA2: Dual oxidase activator 2; HMZ: Homozygous; HTZ: Heterozygous.